Sanofi eyes India for dengue vaccine Phase III study
This article was originally published in Scrip
Executive Summary
Sanofi Pasteur's late-stage dengue vaccine continues to progress across territories with the company now planing a Phase III Indian study in subjects from a range of age groups.